Protecting Lives Worldwide

To ensure rapid supply of vaccines in case of a future pandemic, the European Union collaborates with Bilthoven Biologicals. Our state-of-the-art facilities enable a swift and effective response, saving valuable time when it matters most.

To increase self-sufficiency in vaccine production Bilthoven Biologicals shares it’s poliomyelitis vaccine technology. From teaching QC testing to sharing extensive documentation, our hands-on tech transfers aim to empower local vaccine manufacturing. Building local capacity and supporting independent production.

Our parent company, Serum Institute of India, shares our commitment to making vaccines accessible worldwide. Through large-scale production, they have enabled countries that once could not afford vaccines to protect their populations. Today, we bring that strength to Europe—expanding markets where choices have been limited. In 2025, Bilthoven Biologicals introduced the first of these products to the European market.

Bilthoven Biologicals collaborates with leading global health organizations such as UNICEF and PAHO to provide affordable vaccines in underserved regions. Supporting vulnerable populations with poliomyelitis vaccines and thus strengthen health systems across Africa, the Middle East, Asia, and Europe.